Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lignan compounds for treating or preventing inflammatory disease

A technology of inflammatory diseases and lignans, applied in the field of pharmaceutical compositions for the treatment or prevention of inflammatory diseases, and the treatment or prevention of inflammatory diseases, and can solve problems such as unreported

Active Publication Date: 2008-01-09
AAT 考斯泰克有限公司 +1
View PDF1 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the anti-inflammatory activity of lignans including the above-mentioned macelignans has not been reported so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lignan compounds for treating or preventing inflammatory disease
  • Use of lignan compounds for treating or preventing inflammatory disease
  • Use of lignan compounds for treating or preventing inflammatory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Isolation and purification of lignans from nutmeg

[0073] Separation and purification of lignans

[0074] 75% by volume, 400 ml of methanol was added to 100 g (dry weight) of the dried and pulverized kernels, and the mixture was left to stand at room temperature for 2 days. The above solution was filtered using Whatman No. 2 filter paper. Repeat the above process 2 times. The methanol filtrate was concentrated in vacuo and lyophilized to obtain a crude methanol extract of nucleolus (7 g). The methanol crude extract was fractionated sequentially with ethyl acetate, butanol, and water to obtain ethyl acetate fractions (4.2 g). Utilize silica gel column chromatography (Merck Kieselgel 66; 70-230 order), use hexane and ethyl acetate in the ratio of 10:1 (v / v) the solvent eluting ethyl acetate fractionation, obtains fractionation III ( 1.0g). Using a vacuum rotary concentrator, the solvent was completely removed to obtain a crude extract of the nucleolus. Next, usin...

Embodiment 2

[0084] Investigation of the cytotoxic effect of the lignan compound of the present invention

[0085] Cultivation of RAW264.7 cell line

[0086] In order to investigate the effect of macelignan obtained in Example 1 above on the production of inflammatory response mediators, macrophage RAW264.7 cells were used. Macrophage RAW264.7 cells were purchased from American Tissue Culture Collection (ATCC TIB TIB-71, Rockville, MD, USA). On the DMEM (Dulbecco's Modified Eagle's Medium, Gibco, USA) medium supplemented with heat-inactivated 10% FBS (fetal bovine serum, Gibco, USA), 100 U / ml penicillin G and 100 μm / ml streptomycin, in the medium containing 5 %CO 2 Culture the above cell lines in a 37 °C incubator.

[0087] Determination of Cytotoxicity

[0088] In order to investigate the effect of macelignan of the present invention on the survival rate of RAW264.7 cells, the analysis was based on the reduction of MTT to a purple formazan product by mitochondrial dehydratase (Hayon ...

Embodiment 3

[0091] Investigation of the NO inhibitory effect of the lignan compound of the present invention

[0092] Inhibition of NO production

[0093] Macrophages stimulated by IFN-γ or LPS highly express iNOS and produce a large amount of NO as a mediator of inflammatory response (Miyasaka and Hirata., Immunol. Today., 16:128-130, 1995; Guzik et al., J Physiol. Pharmacol., 54(4):469-487, 2003). Therefore, the effect of macelignan of the present invention on the production of NO in RAW264.7 cells activated by LPS was investigated.

[0094] Dilute RAW264.7 cells to 1 x 10 6 Cells / ml concentration, inoculated into RPMI 1640 medium. After 5 hours, macelignan of the present invention was added at each concentration of 1 to 20 μM, followed by incubation for 2 hours. Next, the medium was treated with LPS (10 µg / ml), and cultured for 24 hours. The control group was treated with LPS only. The amount of NO produced is determined by measuring the NO reaction product NO by using cell cu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the use of an inflammatory disease using the lignan compound. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-a. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

Description

technical field [0001] The present invention claims priority to Korean Patent Application No. 10-2005-0001761 filed on January 7, 2005. [0002] The present invention relates to the use of lignan compounds for treating or preventing inflammatory diseases. More specifically, the present invention relates to a pharmaceutical composition for treating or preventing inflammatory diseases, a method for treating inflammatory diseases using the composition, and an application thereof. The composition contains a lignan compound represented by the general formula I . Background technique [0003] Inflammatory response refers to a series of comprehensive reactions such as enzyme activation, secretion of inflammatory mediators, body fluid infiltration, cell movement, and tissue destruction that occur in local blood vessels and body fluids when tissue (cell) damage or infection occurs Physiological reactions and external symptoms such as erythema, edema, fever, pain, etc., which involv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/357
CPCA61K31/357A61P1/04A61P1/18A61P11/00A61P11/02A61P11/06A61P11/08A61P17/02A61P19/02A61P19/04A61P19/06A61P19/08A61P21/00A61P25/00A61P25/28A61P29/00A61P3/00A61P31/04A61P3/06A61P9/00Y02A50/30
Inventor 黄在宽金道彦郑栽润郑熹彻韩奎利
Owner AAT 考斯泰克有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com